GEP Combined With Radiotherapy in Non-locally Treatable Recurrent NPC
ConditionNasopharynx Cancer
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorZhejiang Cancer Hospital
About this trial
This research aims to assess both effectiveness and safety of combining R-GEP regimen comprising gemcitabine, recombinant human endostatin, and cerexinib with low- and high-dose radiotherapy in managing unresectable recurrent nasopharyngeal carcinoma.
Eligibility criteria
Qualifiers
Patients aged ≥18 years;
ECOG performance status 0-2;
Pathological or clinical imaging diagnosis of recurrent nasopharyngeal carcinoma;
With imaging assessable lesions (assessed by RECIST 1.1 criteria);
Disqualifiers
Subjects who cannot accept or tolerate chemotherapy or radiotherapy for various reasons;
Subjects who can be cured by definitive radiotherapy or surgery;
Subjects who have undergone major surgical procedures within the past 4 weeks or have not fully recovered from such procedures;
Subjects who are currently participating in other drug clinical trials;
Trial design
Treatments tested in this trial
- GEP (Gemcitabine, Recombinant Human Endostatin, and Carrellizumab) Combined With High-low-dose Radiotherapy
Treatment groups
41 Participants
are divided into 1 treatment groupLocations
Sponsors and collaborators
Source ClinicalTrials.gov